8 results on '"Nakamura, Alyson"'
Search Results
2. A Randomized, Double‐Blind, Placebo‐Controlled Trial of Citicoline in Patients with Alcohol Use Disorder.
- Author
-
Brown, E. Sherwood, Van Enkevort, Erin, Kulikova, Alexandra, Escalante, Chastity, Nakamura, Alyson, Ivleva, Elena I., and Holmes, Traci
- Subjects
DIAGNOSIS of alcoholism ,DIAGNOSIS of mental depression ,ALCOHOLISM ,COGNITION ,MENTAL depression ,DESIRE ,NUCLEOTIDES ,REGRESSION analysis ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,BLIND experiment - Abstract
Background: Alcohol use disorder is a major societal and individual burden that exacerbates health outcomes, decreases quality of life, and negatively affects U.S. healthcare spending. Although pharmacological treatments are available for alcohol use disorder, many of them are limited by small effect sizes and used infrequently. Citicoline is a widely available over‐the‐counter supplement with a favorable side effect profile. It acts through cholinergic pathways and phospholipid metabolism. The current report examines the effect of oral citicoline on alcohol use, craving, depressive symptoms, and cognitive outcomes in individuals with alcohol use disorder. Methods: A 12‐week, randomized, double‐blind, parallel‐group, placebo‐controlled, pilot study of citicoline (titrated to 2,000 mg/d) in 62 adults (age 18 to 75) with alcohol use disorder was conducted. Alcohol use, such as number of drinking days, amount used, and number of heavy drinking days, was assessed using the Timeline Followback method and liver enzymes, while alcohol craving was measured using the Penn Alcohol Craving Scale. A neurocognitive battery (e.g., Rey Auditory Verbal Learning Test) and depressive symptoms scale (e.g., Inventory of Depressive Symptomatology Self‐Report) scores were also collected. Data were analyzed using a random regression analysis. Results: The primary outcome analysis was conducted in the intent‐to‐treat sample and consisted of 55 participants (78.2% men and 21.8% women, mean age of 46.47 ± 9.15 years). In the assessment period, the drinking days, on average, represented 77% of the assessed days. Significant between‐group differences were not observed on alcohol use, craving, and cognitive or depressive symptom measures. Citicoline was well tolerated. Conclusions: This proof‐of‐concept study observed that citicoline was well tolerated, but was not associated with a reduction in alcohol use or other outcomes, as compared to placebo. The favorable effects reported with citicoline for cocaine use, cognitive disorders, and other conditions do not appear to extend to alcohol use disorder. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
3. Megestrol Acetate Induces Declarative Memory Changes and Cortisol Suppression in Healthy Volunteers.
- Author
-
Mason, Brittany L., Ivleva, Elena I., Van Enkevort, Erin, Nakamura, Alyson, and Brown, E. Sherwood
- Subjects
COMBINATION drug therapy ,CROSSOVER trials ,HYDROCORTISONE ,MEMORY ,PHENYTOIN ,SYNTHETIC progestagens ,PSYCHOLOGICAL tests ,RANDOMIZED controlled trials ,PHARMACODYNAMICS - Abstract
Background: The effects of the glucocorticoid and progesterone receptor agonist megestrol on declarative memory, and the ability of phenytoin to block these effects, were assessed. Methods: Healthy volunteers received each medication combination (placebo and megestrol, phenytoin and megestrol, and placebo and placebo) using a randomized, crossover design. The Rey Auditory Verbal Learning Test assessed declarative memory. Results: Megestrol was associated with a significant reduction in declarative memory (p = 0.0008), which was attenuated by phenytoin, and was associated with significant cortisol suppression compared to placebo (p < 0.001). Conclusion: Changes in memory and cortisol suppression were found in healthy volunteers given megestrol. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
4. Neurosteroid Levels in Patients With Bipolar Disorder and a History of Cannabis Use Disorders.
- Author
-
Mason, Brittany L., Van Enkevort, Erin, Filbey, Francesca, Marx, Christine E., Park, John, Nakamura, Alyson, Sunderajan, Prabha, and Brown, E. Sherwood
- Published
- 2017
- Full Text
- View/download PDF
5. A Randomized, Double-Blind, Placebo-Controlled Trial of Citicoline for Cocaine Dependence in Bipolar I Disorder.
- Author
-
Brown, E. Sherwood, Todd, Jackie Peterson, Hu, Lisa T., Schmitz, Joy M., Carmody, Thomas J., Nakamura, Alyson, Sunderajan, Prabha, Rush, A. John, Adinoff, Bryon, Bret, Mary Ellen, Holmes, Traci, and Lo, Alexander
- Subjects
NUCLEOTIDES ,TRANQUILIZING drugs ,NOOTROPIC agents ,HAMILTON Depression Inventory ,BIPOLAR disorder ,RESEARCH funding ,SUBSTANCE abuse ,RANDOMIZED controlled trials ,TREATMENT effectiveness ,BLIND experiment ,DISEASE complications ,THERAPEUTICS - Abstract
Copyright of American Journal of Psychiatry is the property of American Psychiatric Publishing, Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2015
- Full Text
- View/download PDF
6. Hippocampal Volume in Healthy Controls Given 3-Day Stress Doses of Hydrocortisone.
- Author
-
Brown, E Sherwood, Jeon-Slaughter, Haekyung, Lu, Hanzhang, Jamadar, Rhoda, Issac, Sruthy, Shad, Mujeeb, Denniston, Daren, Tamminga, Carol, Nakamura, Alyson, and Thomas, Binu P
- Subjects
HYDROCORTISONE ,HIPPOCAMPUS (Brain) ,PHENYTOIN ,CUSHING'S syndrome ,ADRENOCORTICAL hormones ,RANDOMIZED controlled trials ,NEUROPSYCHOPHARMACOLOGY - Abstract
In animal models, corticosterone elevations are associated with hippocampal changes that can be prevented with phenytoin. In humans, Cushing's syndrome and long-term prescription corticosteroid use are associated with a reduction in the hippocampal volume. However, little is known about the effects of short-term corticosteroid administration on the hippocampus. The current report examines changes in the hippocampal volume during a brief hydrocortisone exposure and whether volumetric changes can be blocked by phenytoin. A randomized, double-blind, placebo-controlled, within-subject crossover study was conducted in healthy adults (n=17). Participants received hydrocortisone (160 mg/day)/placebo, phenytoin/placebo, both medications together, or placebo/placebo, with 21-day washouts between the conditions. Structural MRI scans and cortisol levels were obtained following each medication condition. No significant difference in the total brain volume was observed with hydrocortisone. However, hydrocortisone was associated with a significant 1.69% reduction in the total hippocampal volume compared with placebo. Phenytoin blocked the volume reduction associated with hydrocortisone. Reduction in hippocampal volume correlated with the change in cortisol levels (r=−0.58, P=0.03). To our knowledge, this is the first report of structural hippocampal changes with brief corticosteroid exposure. The correlation between the change in hippocampal volume and cortisol level suggests that the volume changes are related to cortisol elevation. Although the findings from this pilot study need replication, they suggest that the reductions in hippocampal volume occur even during brief exposure to corticosteroids, and that hippocampal changes can, as in animal models, be blocked by phenytoin. The results may have implications both for understanding the response of the hippocampus to stress as well as for patients receiving prescription corticosteroids. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
7. A Randomized, Double-Blind, Placebo-Controlled Trial of Pregnenolone for Bipolar Depression.
- Author
-
Brown, E Sherwood, Park, John, Marx, Christine E, Hynan, Linda S, Gardner, Claire, Davila, Domingo, Nakamura, Alyson, Sunderajan, Prabha, Lo, Alexander, and Holmes, Traci
- Subjects
PREGNENOLONE ,BIPOLAR disorder ,THERAPEUTICS ,MENTAL depression ,DISEASE remission ,PREGNANOLONE ,PLACEBOS - Abstract
Depression in bipolar disorder (BPD) is challenging to treat. Therefore, additional medication options are needed. In the current report, the effect of the neurosteroid pregnenolone on depressive symptoms in BPD was examined. Adults (n=80) with BPD, depressed mood state, were randomized to pregnenolone (titrated to 500 mg/day) or placebo, as add-on therapy, for 12 weeks. Outcome measures included the 17-item Hamilton Rating Scale for Depression (HRSD), Inventory of Depressive Symptomatology-Self-Report (IDS-SR), Hamilton Rating Scale for Anxiety (HRSA), and Young Mania Rating Scale (YMRS). Serum neurosteroid levels were assessed at baseline and week 12. Data were analyzed using a mixed model ANCOVA with a between factor of treatment assignment, a within factor (repeated) of visit, and the baseline value, as well as age and gender, as covariates. In participants with at least one postbaseline visit (n=73), a significant treatment by week interaction for the HRSD (F(5,288)=2.61, p=0.025), but not IDS-SR, was observed. Depression remission rates were greater in the pregnenolone group (61%) compared with the placebo group (37%), as assessed by the IDS-SR (χ
2 (1)=3.99, p=0.046), but not the HRSD. Large baseline-to-exit changes in neurosteroid levels were observed in the pregnenolone group but not in the placebo group. In the pregnenolone group, baseline-to-exit change in the HRSA correlated negatively with changes in allopregnanolone (r(22)=−0.43, p=0.036) and pregNANolone (r(22)=−0.48, p=0.019) levels. Pregnenolone was well tolerated. The results suggest that pregnenolone may improve depressive symptoms in patients with BPD and can be safely administered. [ABSTRACT FROM AUTHOR]- Published
- 2014
- Full Text
- View/download PDF
8. A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in Patients with Bipolar Disorder, Mixed or Depressed Phase, and Alcohol Dependence.
- Author
-
Brown, E. Sherwood, Davila, Domingo, Nakamura, Alyson, Carmody, Thomas J., Rush, A. John, Lo, Alexander, Holmes, Traci, Adinoff, Bryon, Caetano, Raul, Swann, Alan C., Sunderajan, Prabha, and Bret, Mary E.
- Subjects
QUETIAPINE ,ALCOHOLISM ,ANALYSIS of covariance ,STATISTICAL correlation ,BIPOLAR disorder ,HEALTH outcome assessment ,RESEARCH funding ,STATISTICS ,COMORBIDITY ,DATA analysis ,TREATMENT effectiveness ,BLIND experiment ,DESCRIPTIVE statistics ,KAPLAN-Meier estimator ,THERAPEUTICS - Abstract
Background Alcohol dependence is common in bipolar disorder ( BPD) and associated with treatment nonadherence, violence, and hospitalization. Quetiapine is a standard treatment for BPD. We previously reported improvement in depressive symptoms, but not alcohol use, with quetiapine in BPD and alcohol dependence. However, mean alcohol use was low and a larger effect size on alcohol-related measures was observed in those with higher levels of alcohol consumption. In this study, efficacy of quetiapine in patients with BPD and alcohol dependence was examined in patients with higher mean baseline alcohol use than in the prior study. Methods Ninety outpatients with bipolar I or II disorders, depressed or mixed mood state, and current alcohol dependence were randomized to 12 weeks of sustained release quetiapine (to 600 mg/d) add-on therapy or placebo. Drinking was quantified using the Timeline Follow Back method. Additional assessment tools included the Hamilton Rating Scale for Depression, Inventory of Depressive Symptomatology- Self- Report, Young Mania Rating Scale, Penn Alcohol Craving Scale, liver enzymes, and side effects. Alcohol use and mood were analyzed using a declining-effects random-regression model. Results Baseline and demographic characteristics in the 2 groups were similar. No significant between-group differences were observed on the primary outcome measure of drinks per day or other alcohol-related or mood measures ( p > 0.05). Overall side effect burden, glucose, and cholesterol were similar in the 2 groups. However, a significant weight increase was observed with quetiapine at week 6 (+2.9 lbs [ SE 1.4] quetiapine vs. −2.0 lbs [ SE 1.4], p = 0.03), but not at week 12. Scores on the Barnes Akathisia Scale increased significantly more ( p = 0.04) with quetiapine (+0.40 [ SE 0.3]) than placebo (−0.52 [ SE 0.3]) at week 6 but not week 12. Retention (survival) in the study was similar in the groups. Conclusions Findings suggest that quetiapine does not reduce alcohol consumption in patients with BPD and alcohol dependence. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.